ADMA Biologics Announces $200M Capital Return Initiative for 2026
ADMA Biologics (ADMA) announced a capital return initiative target of approximately $200M during 2026, including the execution of a $125M accelerated share repurchase agreement with JPMorgan Chase Bank (JPM), National Association. Under the terms of the ASR agreement, ADMA will pay JPMorgan an aggregate upfront amount of $125M and will initially receive approximately 6.4M shares of its common stock on or about March 3, representing approximately 80% of the shares expected to be repurchased under the ASR, based on the closing price of ADMA's common stock of $15.57 per share on February 27. The total number of shares ultimately repurchased will be based on the average of the daily volume-weighted average price of the Company's common stock during the term of the ASR, less an agreed discount, and is expected to be completed within the next five months. At final settlement, the Company may receive additional shares or, under certain limited circumstances, may be required to deliver shares or make a cash payment, pursuant to the terms of the agreement. The ASR agreement was executed pursuant to the Company's existing share repurchase program, under which the Company has up to $500M authorized for repurchases. The Company intends to be opportunistic in deploying these repurchases, which may include repurchases under Rule 10b5-1 trading plans or in other open market transactions in accordance with SEC Rule 10b-18 over the course of 2026, subject to market conditions and other factors.
